Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation‐positive non‐small cell lung cancer

Thoracic Cancer

Hongyan Sun³  Xiaoteng Sun⁴  Xiaoyu Zhai³  Jingfeng Guo²  Yutao Liu³  Jianming Ying¹ 

[1] Department of Pathology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;Hexian Affiliated Memorial Hospital, Southern Medical University, Guangzhou, China;Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;Department of Pathology, Rushan County People's Hospital, Rushan, China

关键词: Body mass index (BMI);    CART;    EGFR active mutation;    gefitinib;    non‐small‐cell lung cancer;   

DOI  :  10.1111/1759-7714.12275

来源: Wiley

【 摘 要 】

Abstract

Background

Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). However, which subgroup of these patients could benefit more from EGFR-TKIs needs to be further explored. In the present study, we explored the predictive factors in such cohorts of patients who received gefitinib.

Methods

The study included 95 patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment. Multivariate analysis of progression-free survival (PFS) was performed using classification and regression tree (CART) analysis to assess the effect of specific variables on PFS in subgroups of patients with similar clinical features.

Results

The median PFS in patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment was 13.3 months (95% confidence interval 9.4–17.2). CART analysis showed an initial split on body mass index (BMI); subsequently, three terminal subgroups were formed. The median PFS in the three subsets ranged from 8.2 to 15.2 months, in which the subgroup with a BMI less than or equal to 20.8 kg/m² had the longest PFS (15.2 months). In addition, PFS in the EGFR exon 19 mutation group was better than in the other mutation site group (10.3 vs. 8.2 months).

Conclusions

BMI and exon 19 mutation may be predictors of PFS in patients with EGFR mutation-positive advanced NSCLC who receive gefitinib treatment. Both active EGFR mutation and patient-specific factors may be used to predict the therapeutic efficacy of EGFR-TKIs.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Thoracic Cancer published by China Lung Oncology Group and Wiley Publishing Asia Pty Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.